Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
about
Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Prevalence of germline TP53 mutations in HER2+ breast cancer patients.Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family RegistryOccurrence of breast cancer subtypes in adolescent and young adult women.Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancerCancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni SyndromeErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.Hereditary breast cancer syndromes and genetic testing.Next generation sequencing is informing phenotype: a TP53 example.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.Routine TP53 testing for breast cancer under age 30: ready for prime time?Clinical implications of germline mutations in breast cancer: TP53.Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark.Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases.Genetic testing in a cohort of young patients with HER2-amplified breast cancer.TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer.Mutant p53 gain of function induces HER2 over-expression in cancer cells.The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing SyndromesLi-Fraumeni Syndrome
P2860
Q34294432-49B92FEB-9E5A-4F15-882D-67E1253C549CQ34324683-32FBB1AA-587A-4AF1-A0DC-B2A9C0EFA404Q34789542-66A4E5EE-E094-476C-B08C-4AE1185E8493Q35735103-DD69A03A-DDDA-47F3-8E65-6F062B8FBBF1Q36245578-718E3938-5C7B-4EAC-8348-223774FD6F20Q36245632-E787FBAF-F692-4C0B-8F7B-68EF6CC5165BQ36775403-439CA3EA-2C7C-4B7B-9E0E-2FAE08A4C984Q36821830-739B98EF-8AF2-4392-98DC-8A490579FAC4Q36914464-2C4800A6-4051-4A50-AB07-0BF36B3C32D9Q37006537-7D601EDA-3371-4E32-AF7F-3B644B263F01Q37084148-623AF9D0-8064-410C-A8FE-695A8E043C90Q37701488-1FC054AB-0FE1-426E-AB51-881A658F3404Q38184454-81F15224-6438-4948-8855-A74DD24F8B7BQ38202612-1B2D2359-B99A-43AA-8CCD-C5B567B03680Q38266306-A5F99108-6688-488D-810C-DC2F0BB4C878Q38783154-A9747E09-14CB-4C0B-9DF1-7F8E1519A97AQ38806371-4972F68C-BE8A-4405-877C-45194D906E1AQ38979257-C1E224C8-6534-4172-9346-780D68BDE09FQ39041480-A5B18FD2-397C-4678-89CB-2A8BEFFA9490Q39199102-743BACB2-B88C-4717-8049-E5C76A4B5CE4Q41616706-F05385F7-348A-48F2-97C0-E55CC18391F4Q47317433-3CFB2D5E-BE93-459C-9C7F-3C13F4FE1614Q47607437-5845C20A-91E0-4C97-A77E-DDC13BB19270Q47894073-CFC1A644-B404-4614-A8CC-BC6FB43F5FD2Q48259632-73F2BEC2-C911-48CD-959E-937375E2692AQ54214613-8CEF8921-4F73-4D6B-BEB3-861842DB0EE4Q54227575-36E0984D-87F5-450E-A80F-943CD9EE8911Q55278806-BB517F53-8FF2-4D7B-B23F-E5D5D00478F6Q55455939-A84263D9-81C6-4B3B-B095-29172BA25918Q57266419-8F0E4ACA-5691-41FC-86FD-D0F3E176013CQ58585566-A0F401B4-3F45-4BC3-8789-1DF6986BB98A
P2860
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@ast
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@en
type
label
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@ast
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@en
prefLabel
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@ast
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@en
P2093
P2860
P356
P1433
P1476
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
@en
P2093
Amal Melhem-Bertrandt
Angelica M Gutierrez-Barrera
Banu K Arun
Diane D Liu
Elias Obeid
Gabriel N Hortobagyi
Jasmina Bojadzieva
Jennifer K Litton
Kaylene J Ready
Louise C Strong
P2860
P304
P356
10.1002/CNCR.26377
P407
P577
2011-07-14T00:00:00Z